<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038673</url>
  </required_header>
  <id_info>
    <org_study_id>5878-CL-0101</org_study_id>
    <nct_id>NCT02038673</nct_id>
  </id_info>
  <brief_title>An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors</brief_title>
  <official_title>An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to determine the tolerability, safety, pharmacokinetics
      (PK), pharmacodynamics (PD), and efficacy of oral ASP5878 in participants with solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of two parts. In the dose-escalation part, ASP5878 (orally available
      novel small-molecule FGFR 1,2,3 and 4 inhibitor, multiple dosing once-a-day (q.d.), multiple
      dosing twice-a-day (b.i.d.) or 5-day on/2-day off dosing twice-a-day (5on-2off)) is
      administered to participants with solid tumors in an increasing dose manner, and the
      tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ASP5878
      are evaluated in these participants. Cycle 0 consists of 3 days and Cycle 1 and subsequent
      cycles consist of 28 days each in the dose-escalation part. In the expansion part, 16mg
      twice-a-day 5-day on/2-day off dose of ASP5878 (5on-2off) is administered to participants
      with solid tumors and safety, PK, PD and efficacy of ASP5878 are evaluated. The expansion
      part starts from Cycle 1 and each cycle consists of 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2013</start_date>
  <completion_date type="Actual">July 19, 2017</completion_date>
  <primary_completion_date type="Actual">July 19, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part: Safety assessed by Adverse Events (AEs)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part:Safety assessed by Vital signs</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Blood pressure, pulse rate and body temperature, Until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part:Safety assessed by Body weight</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part:Safety assessed by Laboratory tests</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Hematology, blood biochemistry, blood coagulation tests and urinalysis, until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part:Safety assessed by 12-lead ECGs</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>ECG: Electrocardiogram, until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part: Ophthalmology</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Eyesight, funduscopy, slit lamp microscopy, and Optical Coherence Tomography, until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part: Bone density measurement</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part: Computed tomography (CT) Imaging assessment</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expansion part only: Echocardiogram</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: Pharmacokinetics (PK) parameter of ASP5878 in plasma: Cmax</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>Cmax: Maximum concentration, Cycle 0: single dose, Cycle 1: multiple dose after Cycle 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part:PK parameter of ASP5878 in plasma: tmax</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>tmax: Time of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part:PK parameter of ASP5878 in plasma: AUClast</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>AUClast: Area under the concentration-time curve from the time of dosing extrapolated to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PK parameter of ASP5878 in plasma: AUCinf</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PK parameter of ASP5878 in plasma: t1/2</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PK parameter of ASP5878 in plasma: CL/F</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>CL/F: Apparent total systemic clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PK parameter of ASP5878 in plasma: Vz/F</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>Vz/F: Apparent volume of distribution during the terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PK parameter of ASP5878 in urine: Ae</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>Ae: Amount of ASP5878 excreted into the urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PK parameter of ASP5878 in urine: CLR</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>CLR: Renal clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: Pharmacodynamic (PD) parameter: Serum FGF23 concentrations</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>FGF: Fibroblast Growth Factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PD parameter: Serum inorganic phosphorus concentrations</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PD parameter: Serum calcium concentrations</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PD parameter: Serum iPTH concentrations</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>iPTH: Intact Parathyroid Hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PD parameter: Serum calcitriol concentrations</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: Cmax</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: tmax</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: AUClast</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: AUCinf</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: t1/2</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: CL/F</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: Vz/F</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PD parameter: Serum FGF19 concentrations</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PD parameter: Serum FGF23 concentrations</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PD parameter: Serum inorganic phosphorus concentrations</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PD parameter: Serum iPTH concentrations</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PD parameter: Serum calcitriol concentrations</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PD parameter: Serum 7α-hydroxy-4-cholesten-3-one</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: Overall response</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Antitumor activity evaluated based on RECIST version 1.1, until one of the discontinuation criteria is met. Antitumor response is rated on a 4-level scale shown below (complete response [CR], partial response [PR], progressive disease [PD] and stable disease [SD]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: Maximum Shrinkage in Target Lesion</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Best percent change from baseline in the sum of diameters of all target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: Progression free survival (PFS)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Time from the start of the study treatment until death from any cause or Progressive Disease assessed according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: Time to progression (TTP)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Time from the start of the study treatment until Progressive Disease assessed according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: Time to treatment failure (TTF)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Time from the start of the study drug treatment until discontinuation of study drug treatment for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: Overall survival (OS)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Time from randomization to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose escalation part 0.5 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation part 1.0 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation part 2.0 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation part 2.0 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation part 4.0 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation part 6.0 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation part 10.0 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation part 20.0 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation part 16.0 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion part Urothelial Carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion part Hepatocellular Carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion part Squamous Cell Lung Carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP5878</intervention_name>
    <description>oral</description>
    <arm_group_label>Dose escalation part 0.5 mg QD</arm_group_label>
    <arm_group_label>Dose escalation part 1.0 mg QD</arm_group_label>
    <arm_group_label>Dose escalation part 10.0 mg BID</arm_group_label>
    <arm_group_label>Dose escalation part 16.0 mg BID</arm_group_label>
    <arm_group_label>Dose escalation part 2.0 mg BID</arm_group_label>
    <arm_group_label>Dose escalation part 2.0 mg QD</arm_group_label>
    <arm_group_label>Dose escalation part 20.0 mg BID</arm_group_label>
    <arm_group_label>Dose escalation part 4.0 mg BID</arm_group_label>
    <arm_group_label>Dose escalation part 6.0 mg BID</arm_group_label>
    <arm_group_label>Expansion part Hepatocellular Carcinoma</arm_group_label>
    <arm_group_label>Expansion part Squamous Cell Lung Carcinoma</arm_group_label>
    <arm_group_label>Expansion part Urothelial Carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed solid tumor.

          -  Participant must meet at least one of the following criteria in the judgment of the
             investigator or sub-investigator:

               -  Disease progression despite standard therapies

               -  Progressive disease without any standard therapies established

               -  Standard therapies are considered intolerable

          -  Eastern Cooperative Oncology Group performance status 0 or 1.

          -  Predicted life expectancy ≥ 12 weeks in the judgment of the investigator or
             sub-investigator.

        Exclusion Criteria:

          -  Participant with ≥ Grade 2 (CTCAE v 4.0-JCOG) persistent symptoms and objective
             findings due to the toxicity attributable to prior treatment with antitumor effect
             (except alopecia).

          -  Participant who received a prior treatment intended for antitumor effect (medication,
             surgery, radiotherapy, etc.) within 4 weeks prior to the planned first day of study
             drug dosing (or participant who received mitomycin C or Nitrosourea within 6 weeks
             prior to the planned first day of study drug dosing).

          -  A major surgical procedure within 4 weeks prior to the planned first day of study drug
             dosing or a surgical procedure is planned during the course of the study.

          -  Participant who were treated with other investigational drug or medical device within
             4 weeks prior to the planned first day of study drug dosing.

          -  Participant who has a history of organ transplantation.

          -  Participant with a brain metastasis with symptoms or requiring treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site US402</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US401</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US404</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US406</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US410</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US403</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP122</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP108</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP115</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP120</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP116</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP113</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP103</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP111</name>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP119</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP101</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP109</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP110</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP112</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP117</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP121</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP104</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP106</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP118</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP124</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP102</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP107</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP123</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR202</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR201</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR203</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR204</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW302</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW301</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW303</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Afghanistan</country>
  </removed_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=262</url>
    <description>Link to results on the Astellas Clinical Study Results website</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <last_update_submitted>October 18, 2018</last_update_submitted>
  <last_update_submitted_qc>October 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP5878</keyword>
  <keyword>FGFR 1,2,3 and 4 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

